State Street’s Fulgent Genetics FLGT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$8.42M Buy
529,399
+35,735
+7% +$776K ﹤0.01% 2704
2025
Q4
$13M Sell
493,664
-8,332
-2% -$216K ﹤0.01% 2497
2025
Q3
$11.3M Sell
501,996
-11,801
-2% -$243K ﹤0.01% 2571
2025
Q2
$10.2M Buy
513,797
+7,012
+1% +$137K ﹤0.01% 2592
2025
Q1
$8.56M Sell
506,785
-312,637
-38% -$5.32M ﹤0.01% 2628
2024
Q4
$15.1M Buy
819,422
+25,877
+3% +$505K ﹤0.01% 2379
2024
Q3
$17.2M Buy
793,545
+10,868
+1% +$243K ﹤0.01% 2302
2024
Q2
$15.4M Sell
782,677
-41,800
-5% -$873K ﹤0.01% 2303
2024
Q1
$17.9M Buy
824,477
+11,545
+1% +$287K ﹤0.01% 2243
2023
Q4
$23.5M Buy
812,932
+40,856
+5% +$1.09M ﹤0.01% 2123
2023
Q3
$20.6M Buy
772,076
+15,915
+2% +$543K ﹤0.01% 2163
2023
Q2
$28M Sell
756,161
-42,920
-5% -$1.5M ﹤0.01% 2025
2023
Q1
$24.9M Sell
799,081
-6,994
-0.9% -$225K ﹤0.01% 2079
2022
Q4
$24M Buy
806,075
+49,718
+7% +$1.78M ﹤0.01% 2108
2022
Q3
$28.8M Buy
756,357
+38,121
+5% +$1.91M ﹤0.01% 1965
2022
Q2
$39.2M Buy
718,236
+22,153
+3% +$1.22M ﹤0.01% 1812
2022
Q1
$43.4M Buy
696,083
+70,764
+11% +$4.66M ﹤0.01% 1858
2021
Q4
$62.9M Buy
625,319
+3,768
+0.6% +$331K ﹤0.01% 1657
2021
Q3
$55.9M Buy
621,551
+12,372
+2% +$1.12M ﹤0.01% 1730
2021
Q2
$56.2M Buy
609,179
+150,062
+33% +$12M ﹤0.01% 1760
2021
Q1
$44.4M Buy
459,117
+47,260
+11% +$4.88M ﹤0.01% 1823
2020
Q4
$21.5M Buy
411,857
+146,193
+55% +$6.11M ﹤0.01% 2208
2020
Q3
$10.6M Buy
265,664
+130,881
+97% +$4.1M ﹤0.01% 2408
2020
Q2
$2.16M Buy
+134,783
New +$2.06M ﹤0.01% 3151
2017
Q2
Sell
-50,076
Closed -$549K 3714
2017
Q1
$549K Buy
+50,076
New +$592K ﹤0.01% 3368

Other funds holding FLGT

State Street's FLGT Position: Q1 2026 in Review

State Street increased its Fulgent Genetics (FLGT) stake by 7.2% in Q1 2026, buying an estimated $776K and bringing the position to 529,399 shares worth $8.42M. The position accounts for ﹤0.01% of the portfolio, ranked #2704.

State Street first reported a position in FLGT in Q1 2017 and has held it in 25 quarters since. The position peaked at $62.9M in Q4 2021. 157 funds tracked by Wall St. Rank hold FLGT as of Q1 2026.

  • State Street held 529,399 shares of Fulgent Genetics worth $8.42M as of Q1 2026.
  • State Street bought 35,735 Fulgent Genetics shares in Q1 2026, an estimated $776K.
  • Fulgent Genetics made up ﹤0.01% of State Street's portfolio in Q1 2026, its #2704 holding.
  • State Street first reported a position in Fulgent Genetics in Q1 2017 and has held it in 25 quarters since.
  • State Street's Fulgent Genetics position peaked at $62.9M in Q4 2021.
  • 157 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.